Quest Highlights Diagnostics Pipeline As Key Component Of Celera Purchase
This article was originally published in The Gray Sheet
Executive Summary
Quest Diagnostics will expand its molecular diagnostic product offerings and gain a substantial biomarker R&D pipeline while boosting its cardiovascular testing services business through the purchase of Celera for $344 million in cash.